3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Cirrhosis
1
Hepato Cellular Carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
tremelimumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled